Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer Nancy Egerton Mini Review Open access 01 October 2010 Pages: 1005 - 1012
Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93) Ritesh RathoreAriel BirnbaumNeal Ready Original Article 04 February 2010 Pages: 1013 - 1017
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer Elaine T. LamJessie L.- S. AuMiguel A. Villalona-Calero Original Article 28 January 2010 Pages: 1019 - 1029
Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats Kazuma HamadaYoshihisa ShitaraToshiharu Horie Original Article 30 January 2010 Pages: 1031 - 1038
Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphoma Joel S. OwenMurad MelhemBradley Kahl Original Article 06 February 2010 Pages: 1039 - 1049
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer Andrew H. KoAlan P. VenookMargaret A. Tempero Original Article 04 February 2010 Pages: 1051 - 1057
Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma Olivier MirStanislas RopertFrançois Goldwasser Original Article 13 February 2010 Pages: 1059 - 1063
An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma Seiji NaitoTaiji TsukamotoHideyuki Akaza Original Article 16 February 2010 Pages: 1065 - 1070
Sonodynamically induced apoptosis and active oxygen generation by gallium–porphyrin complex, ATX-70 Nagahiko YumitaKazuho OkudairaShin-ichiro Umemura Original Article 05 March 2010 Pages: 1071 - 1078
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies Paul K. PaikCharles M. RudinLee M. Krug Original Article 18 February 2010 Pages: 1079 - 1085
Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement Apostolia M. TsimberidouStacy MoulderRazelle Kurzrock Original Article 04 March 2010 Pages: 1087 - 1093
Inhibition of established subcutaneous murine tumour growth with topical Melaleuca alternifolia (tea tree) oil Sara J. GreayDemelza J. IrelandManfred W. Beilharz Original Article 21 February 2010 Pages: 1095 - 1102
Resistance to platinum-based chemotherapy in lung cancer cell lines Jianli ChenNashwa EmaraHenry Simpkins Original Article 21 February 2010 Pages: 1103 - 1111
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol Mark A. DicksonManish A. ShahGary K. Schwartz Original Article 21 February 2010 Pages: 1113 - 1121
Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma Hidenari NagaiTeppei MatsuiYasukiyo Sumino Original Article 24 February 2010 Pages: 1123 - 1129
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer Yi-kang ShiZhong-hua LiPeng Wang Original Article 14 September 2010 Pages: 1131 - 1140
Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer Laurent ClaretJian-Feng LuRené Bruno Original Article 25 September 2010 Pages: 1141 - 1149
Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients Jian-Feng LuLaurent ClaretYu-Nien Sun Original Article 25 September 2010 Pages: 1151 - 1158
Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study Yoshihiro TanakaKazuhiro YoshidaTakao Takahashi Clinical Trial Report Open access 28 September 2010 Pages: 1159 - 1165
Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study Arantza Fariña-SarasquetaGesina van LijnschotenAdriaan J. C. van den Brule Short Communication 28 July 2010 Pages: 1167 - 1171
Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Rao N. V. S. MamidiSteve WengMan-Cheong Fung Short Communication 27 July 2010 Pages: 1173 - 1184